PillNewsroom
News
A daily, curated feed of drug and pharmaceutical news. FDA actions, approvals, recalls, shortages, and the companies behind them.
STAT — PharmaJul 23, 2026
STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.
Read at STAT — Pharma →
STAT — PharmaJul 23, 2026
STAT+: European regulators take steps to bolster clinical trial transparency
The European Medicines Agency is taking what advocacy groups are calling unexpectedly “rapid action” to ensure that clinical trial results are made public as required by law.
Read at STAT — Pharma →
STAT — PharmaJul 23, 2026
STAT+: Popular insulin product enters shortage as other pens leave market
The Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.
Read at STAT — Pharma →
BioPharma DiveJul 23, 2026
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.
Read at BioPharma Dive →STAT — PharmaJul 23, 2026
FDA panel confronting peptide controversy
Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
Read at STAT — Pharma →
STAT — PharmaJul 23, 2026
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk
Read at STAT — Pharma →
STAT — PharmaJul 23, 2026
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
A leading advocacy group petitioned the FDA to ban direct-to-consumer advertising of prescription medicines.
Read at STAT — Pharma →
STAT — PharmaJul 23, 2026
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
On analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.
Read at STAT — Pharma →
STAT — PharmaJul 23, 2026
STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel
FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.
Read at STAT — Pharma →
BioPharma DiveJul 22, 2026
GSK lung cancer drug gets speedy approval following $10.6B deal
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
Read at BioPharma Dive →FDA — Press ReleasesJul 22, 2026
FDA Announces First Participant Selected for TEMPO for Digital Health Devices Pilot
The U.S. Food and Drug Administration today announced the first manufacturer selected for the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot.
Read at FDA — Press Releases →BioPharma DiveJul 22, 2026
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
Read at BioPharma Dive →BioPharma DiveJul 22, 2026
Trump threatens tariffs on imported generic drugs
While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the specifics — prove more disruptive.
Read at BioPharma Dive →STAT — PharmaJul 22, 2026
STAT+: Pharma tries to tamp down broad China restrictions
AI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readout
Read at STAT — Pharma →
BioPharma DiveJul 22, 2026
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.
Read at BioPharma Dive →BioPharma DiveJul 21, 2026
Agios scraps sickle cell drug
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
Read at BioPharma Dive →BioPharma DiveJul 21, 2026
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”
Read at BioPharma Dive →BioPharma DiveJul 21, 2026
Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
Read at BioPharma Dive →STAT — PharmaJul 21, 2026
STAT+: Anthropic deepens work with rare disease drugs
Novo Nordisk sues Eli Lilly over GLP-1s, Medicare pricing plans, and more biotech news from The Readout
Read at STAT — Pharma →
STAT — PharmaJul 21, 2026
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
Novo Nordisk sued Eli Lilly for allegedly running “deceptive” ads to make its obesity and diabetes drugs appear more effective
Read at STAT — Pharma →STAT — PharmaJul 21, 2026
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.
Read at STAT — Pharma →
STAT — PharmaJul 21, 2026
STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilots
A coalition of biotech firms is lobbying to exclude orphan drugs from new federal pilot programs aimed at lowering Medicare drug costs.
Read at STAT — Pharma →
BioPharma DiveJul 20, 2026
Pain drugmaker Latigo outlines plans to go public
The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.
Read at BioPharma Dive →STAT — PharmaJul 20, 2026
STAT+: The next step of site-neutral, and a fiery PBM hearing
Medicare proposes to reduce payments to hospitals for certain drugs and imaging services.
Read at STAT — Pharma →
BioPharma DiveJul 20, 2026
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.
Read at BioPharma Dive →BioPharma DiveJul 20, 2026
[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services
This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.
Read at BioPharma Dive →STAT — PharmaJul 20, 2026
STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer
Bristol Myers Squibb is the third drugmaker in nine months to announce it is building the largest AI supercomputer in the life sciences industry.
Read at STAT — Pharma →
STAT — PharmaJul 20, 2026
STAT+: State audit of Medicaid records points to methods used by PBMs to obscure drug costs
An audit of state Medicaid records revealed how PBMs are using complicated tactics for handling prescription drug claims that ultimately overcharge taxpayers.
Read at STAT — Pharma →
FDA — Press ReleasesJul 17, 2026
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemi
Read at FDA — Press Releases →STAT — PharmaJul 17, 2026
STAT+: The end for GSK’s chronic cough treatment
Sonothera's ultrasound gene therapy delivery, a new Alzheimer's drug controversy, and more biotech news from The Readout
Read at STAT — Pharma →
BioPharma DiveJul 17, 2026
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.
Read at BioPharma Dive →BioPharma DiveJul 17, 2026
Compounders maintain a firm grip on the GLP-1 market
Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.
Read at BioPharma Dive →STAT — PharmaJul 17, 2026
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Read at STAT — Pharma →
STAT — PharmaJul 17, 2026
STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
The number of active medication shortages in the U.S. rose to 227 in the second quarter of 2026
Read at STAT — Pharma →STAT — PharmaJul 17, 2026
STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claims
Sonothera is developing a new way to deliver genes into cells that, if borne out, could have a big impact on muscular dystrophy and other diseases.
Read at STAT — Pharma →
STAT — PharmaJul 16, 2026
STAT+: FDA approves Merck’s oral PCSK9 drug, a first
Kalshi allows bets on clinical trial outcomes, Eli Lilly buys a psychedelic medicine, and more biotech news from The Readout
Read at STAT — Pharma →
STAT — PharmaJul 16, 2026
STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals
Prediction markets have permeated the worlds of sports, politics, and reality television shows. Now, the biopharma industry could be next.
Read at STAT — Pharma →
FDA — Press ReleasesJul 15, 2026
FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in Horses
The FDA today issued an Emergency Use Authorization (EUA) for Ivermectin Liquid for Horses (ivermectin oral solution) for the short-term prevention of New World screwworm (NWS) infestations (myiasis) in horses when administered within 24 hours of birth or at the time of initial wound care.
Read at FDA — Press Releases →STAT — PharmaJul 15, 2026
Cassidy grills Trump nominee on past vaccine comments in heated exchange
Sean Kaufman, Trump's pick for a key pandemic preparedness role, has questioned vaccines and criticized the CDC.
Read at STAT — Pharma →
STAT — PharmaJul 15, 2026
STAT+: Bipartisan lawmakers want to require U.S. to probe reliance on foreign-made drugs, ingredients
A trio of bipartisan lawmakers reintroduced a bill requiring the FTC and Treasury to investigate whether the U.S. relies too heavily on foreign countries as part of its pharmaceutical supply…
Read at STAT — Pharma →
Sources: reputable US pharmaceutical news outlets and FDA press releases, via their public feeds. Links open the publisher's site and carry no endorsement. Pillstats is a referrer, not a republisher.